| Nov 6 |
An RNAi renaissance is creating a new generation of startups
|
| Oct 31 |
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
|
| Oct 30 |
Avidity Biosciences initiates biomarker cohort in early stage trial for muscular dystrophy treatment
|
| Oct 30 |
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy
|
| Oct 18 |
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
|
| Oct 4 |
Why Avidity Biosciences Zoomed to a 12% Gain This Week
|
| Oct 4 |
FDA lifts clinical hold on Avidity’s lead antibody conjugate therapy trial
|
| Oct 3 |
Avidity gets FDA partial clinical hold lifted on DM1 drug candidate
|
| Oct 3 |
Avidity Biosciences: Good Prospects, But We Are A Little Late
|
| Oct 3 |
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
|
